Jiangsu Nanfang Medical603880.SHValuation Analysis

As of Oct 19, 2026, Jiangsu Nanfang Medical (603880.SH) trades at a negative P/E (-21.87x, due to a recent net loss), P/B of 14.60x, P/S of 4.30x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 97th percentile over the trailing 10Y window (vs. 91st percentile over 3Y); P/S sits at the 81st percentile over the trailing 10Y window (vs. 92nd percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 97th percentile within its industry and the 96th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangsu Nanfang Medical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.